There are currently 92 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
NCT01730781
Recruiting
The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with... Read More
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
11/02/2023
Locations: Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Conditions: Schizophrenia, Cannabis Dependence, Prodromal for Psychotic Illness, Family History of Alcoholism, Healthy Control, Opioid-use Disorder, Post Traumatic Stress Disorder
Register for Updates
Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness
NCT04940663
Recruiting
The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions among these experiences in daily life and how they, and their neurobehavioral predictors, are linked to day-to-day functioning. The findings of this project could provide novel targets for therapeutic... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
10/17/2023
Locations: Massachusetts General Hospital, Charlestown, Massachusetts
Conditions: Psychosis, Schizophrenia
Register for Updates
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
NCT05389787
Recruiting
This is a single-site, sham-controlled, randomized trial in a total of 60 subjects between ages 18 and 40 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms: Arm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS Each participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic reso... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
09/12/2023
Locations: Zucker Hillside Hospital, New York, New York
Conditions: Schizophrenia, Cerebellar Function, Condition
Register for Updates
Adapting the Tumor Board Model for Mental Illness and Cancer
NCT05837598
Recruiting
This study examines the feasibility and acceptability of a virtual tumor board for cancer and mental illness for patients with serious mental illness and a new cancer diagnosis. The study also examines the impact on patient care, psychiatric symptoms, and clinician self-efficacy in managing this population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Mass General/North Shore Center for Outpatient Care, Danvers, Massachusetts
Conditions: Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer
Register for Updates
Siltuximab in Schizophrenia
NCT02796859
Recruiting
This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Siltuximab (Sylvant) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia. Siltuximab (structural formula C6450H9932N1688O2016S50) is a recombinant chimeric (human-murine) anti-human interleukin-6 (IL-6) monoclonal antibody. Siltuximab is formulated as a concentrate for solution for infusion, and will be administered by intravenous infusion. The investigators propose a 9-... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/20/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Schizophrenia, Psychotic Disorders
Register for Updates
Tocilizumab in Schizophrenia
NCT02874573
Recruiting
This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Tocilizumab (Actemra) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia. Tocilizumab (structural formula C6428H9976N1720O2018S42) is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin G1 (IgG1) subclass. Tocilizumab is formulated as a concentrate for solution for infusion, and will be administered by intravenous in... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/20/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Schizophrenia, Psychotic Disorders
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Pillar Clinical Research, Bentonville, Arkansas +120 locations
Conditions: Schizophrenia
Register for Updates
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
NCT03495024
Recruiting
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2019
Locations: Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania
Conditions: Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Register for Updates